

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.*

*This joint announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company or the Offeror nor is it a solicitation of any vote or approval in any jurisdiction. This joint announcement is not for release, publication or distribution in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.*



**Grand Full Development Limited**  
(創隆發展有限公司)  
*(Incorporated in Hong Kong with  
limited liability)*

**Bloomage BioTechnology  
Corporation Limited**  
華熙生物科技有限公司  
*(Incorporated in the Cayman Islands  
with limited liability)*  
**(Stock Code: 00963)**

## **JOINT ANNOUNCEMENT**

**(1) PROPOSED PRIVATIZATION OF  
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED  
BY GRAND FULL DEVELOPMENT LIMITED  
BY WAY OF A SCHEME OF ARRANGEMENT  
(UNDER SECTION 86 OF THE COMPANIES LAW)**

**AND**

**(2) PROPOSED WITHDRAWAL OF LISTING OF THE SHARES OF  
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED  
EXTENSION OF TIME FOR DESPATCH OF  
THE SCHEME DOCUMENT**

As more time is required to accommodate the timetable of the Grand Court, an application for consent has been made to the Executive and the Executive has indicated that it is minded to grant consent for an extension to the time limit for despatching the Scheme Document from 10 July 2017 to 8 September 2017.

A detailed timetable for the Proposal, the Scheme and the Option Offer will be set out in the Scheme Document and in the announcement to be jointly made by the Offeror and the Company upon despatch of the Scheme Document.

**Warning: Shareholders, Optionholders and potential investors should exercise caution when dealing in the Shares and any options or other rights in respect of them. The implementation of the Proposal, the Scheme and/or the Option Offer is subject to the satisfaction of the Conditions being fulfilled or waived, as applicable, and thus the Proposal, the Scheme and the Option Offer may or may not be implemented and the Scheme may or may not become effective. Persons who are in doubt as to the action they should take should consult their licensed securities dealers or registered institutions in securities, bank manager, solicitor or other professional advisers.**

## INTRODUCTION

Reference is made to the joint announcement issued by the Offeror and the Company regarding the Proposal, the Scheme and the Option Offer dated 19 June 2017 (the “**Joint Announcement**”). Unless otherwise defined herein, terms used herein shall have the same meanings as defined in the Joint Announcement.

## EXTENSION OF THE TIME FOR DESPATCH OF THE SCHEME DOCUMENT

Under Rule 8.2 of the Takeovers Code, unless the Executive’s consent is obtained, the Scheme Document should normally be despatched to the Scheme Shareholders and the Optionholders within 21 days of the date of the Joint Announcement, which in this case would be on or before 10 July 2017.

As stated in the Joint Announcement, the Scheme will only become effective if, among other conditions, the Scheme is approved at the Court Meeting. A court hearing is required for the Grand Court to issue its directions for convening the Court Meeting. As more time is required to accommodate the timetable of the Grand Court, an application for consent has been made to the Executive and the Executive has indicated that it is minded to grant consent for an extension to the time limit for despatching the Scheme Document from 10 July 2017 to 8 September 2017.

A detailed timetable for the Proposal, the Scheme and the Option Offer will be set out in the Scheme Document and in the announcement to be jointly made by the Offeror and the Company upon despatch of the Scheme Document.

**Warnings:**

**Shareholders, Optionholders and potential investors should be aware that the implementation of the Proposal, the Scheme and/or the Option Offer is subject to the Conditions being fulfilled or waived, as applicable, and thus the Proposal, the Scheme and the Option Offer may or may not be implemented and the Scheme may or may not become effective.**

**Shareholders, Optionholders and potential investors should therefore exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their licensed securities dealers or registered institutions in securities, bank manager, solicitor or other professional advisers.**

By Order of the Board of  
**Grand Full Development Limited**  
(創隆發展有限公司)  
**Zhao Yan**  
*Director*

By Order of the Board of  
**Bloomage BioTechnology  
Corporation Limited**  
(華熙生物科技股份有限公司)  
**Gong Anmin**  
*Director*

Hong Kong, 10 July 2017

*As at the date of this joint announcement, the sole director of the Offeror is Ms. Zhao.*

*The sole director of the Offeror accepts full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Group) and confirms, having made all reasonable enquiries, that to the best of her knowledge, opinions expressed in this joint announcement (other than those expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.*

*As at the date of this joint announcement, the Directors are:*

*Executive Directors:*  
*Ms. Zhao Yan*  
*Mr. Jin Xuekun*  
*Mr. Gong Anmin*  
*Ms. Wang Aihua*

*Non-executive Director:*  
*Mr. Yau Wai Yan*

*Independent non-executive Directors:*  
*Ms. Zhan Lili*  
*Mr. Li Junhong*  
*Mr. Xue Zhaofeng*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Offeror) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by the Offeror) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.*